TESTIMONIALS

Testimonials From 2023

At Hanson Wade, we have 8 years of experience in organizing industry-leading gene therapy conferences, helping drug developers navigate the unique development, manufacturing, and commercial challenges they face.

We pride ourselves on bringing together the foremost voices to lead collegial discussions around the pressing topics of today.

Don’t just take it from us though. Here are what previous attendees at last year’s inaugural Gene Therapy Potency Assay Summit had to say on their experience with us:

“A collegial meeting with experienced industry leaders demonstrating their way of running various potency assays and describing their experience in working with the FDA, so that others could compare, contrast and learn for the future”

Insmed Logo
Solid Biosciences

“I appreciated how focused the summit was. Having colleagues that are working on the same topic share their insight, experience and thoughts is very valuable. Presentations were very high quality and informative; panel discussions were insightful”

“It was very relevant to what I'm currently working on. It was good to hear about the FDA expected requirements and how different people have coped with that”

Oxford Biomedica
Spark Therapeutics

“It was a great success for networking, discussions and valuable content, as well insights on gene therapy potency assay. Experienced with clear direction on improving cell-based potency assay for generating reliable & reproducible results”

“I gained a lot of knowledgeable information from the presenters. I felt that all of the presenters were extremely approachable and experts on what they were talking about”

Adaptimmune Therapeutics
Janssen

“This is a very well-organized event. The chosen topics are valuable in the current field. Being able to share experiences, especially challenges with people in the same field is perhaps what I enjoy the most”

“Relevant talks and great networking opportunities”

Avance Biosciences
Beacon Therapeutics

“It gave me a good feel that our struggles and pain were similar to other companies, and we were on the right track”